Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease

NCT04837131 is registered in ClinicalTrials.gov with Michael M. Pham as lead sponsor.

NCT NCT04837131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04837131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease
Lead sponsor
Michael M. Pham
Phase
Phase 2
Overall status
Terminated
Start date
April 28, 2021
Completion date
February 23, 2024
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous scleroderma, diffuse cutaneous systemic sclerosis, diffuse scleroderma, diffuse systemic sclerosis, interstitial lung disease, progressive scleroderma, progressive systemic sclerosis, pulmonary fibrosis interstitial, scleroderma, scleroderma of lung, scleroderma with pulmonary involvement, scleroderma, diffuse, scleroderma, systemic, scleroderma;progressive, systemic sclerosis, systemic sclerosis pulmonary, systemic sclerosis with lung involvement, systemic sclerosis, diffuse, systemic; sclerosis, progressive